Kalm Therapeutics Gains Key Advisor as It Advances Clinical Pipeline
Kalm Therapeutics, a biotechnology firm based at the HudsonAlpha Institute for Biotechnology in Huntsville, said it has added Dr. Peter Lio, a Harvard-trained dermatologist and researcher, as both an investor and member of its Scientific Advisory Board. The move marks a key step for the company as it advances clinical development of its experimental patch therapy for inflammatory skin diseases and approaches several major milestones in its pipeline.
Dr. Lio is a Harvard-trained dermatologist and clinical researcher located in Chicago, IL. He is one of the foremost authorities on atopic dermatitis and inflammatory skin disorders and has been on the National Eczema Association’s Board of Directors for over eight years. He currently serves as Clinical Assistant Professor of Dermatology and Pediatrics at Northwestern University Feinberg School of Medicine and is the founding director of the Chicago Integrative Eczema Center.
“We are honored to welcome Dr. Lio to our advisory board at this pivotal phase of growth,” said AJ Singhal, CEO of Kalm Therapeutics. “His deep clinical expertise and long-standing commitment to innovation in dermatology will be instrumental as we advance our lead programs toward late-stage development and explore strategic partnerships.”
Dr. Lio has authored over 100 peer-reviewed publications and is actively involved in translational research and clinical trials. His appointment provides additional validation of Kalm’s scientific approach and its potential to address large, underserved markets with significant commercial opportunity.
“Kalm Therapeutics has a clear focus on patient-centered innovation while pursuing a novel patch system which will protect and treat the inflamed skin,” said Dr. Lio. “I look forward to advising the team as they advance their pipeline and work to bring meaningful new treatments to market.”
Dr. Lio joins Kalm at a time of growing momentum, as the company prepares for upcoming clinical data readouts and strategic initiatives to expand its intellectual property portfolio and clinical reach.
